Specifically, authors found higher expression of BCL-6 in exosomes from DLBCL and FL patients than in healthy controls, and BCL-6 and C-MYC mRNAs as predictor markers of shorter OS and worse PFS. This evidence concerns the gene BCL6 and diffuse large B-cell lymphoma.